Optimi Health Completes Largest-to-Date MDMA Export to Australia for PTSD Therapy
Vancouver, British Columbia--(Newsfile Corp. - May 8, 2025) - Optimi Health Corp. (CSE: OPTI) (OTCQX: OPTHF) (FSE: 8BN) ("Optimi" or the "Company"), a Canadian drug manufacturer and formulator of GMP-grade MDMA and natural psilocybin, has completed its largest international export to date of MDMA capsules to Australia, supporting the treatment of Post-Traumatic Stress Disorder (PTSD) under the country's Authorised Prescriber Scheme.The shipment, conducted in partnership with Mind Medicine Australia, included 1,000 GMP MDMA capsules in both 40mg and 60mg strengths....
2025-05-08 7:00 AM EDT
Optimi Health Obtains U.S. FDA Drug Establishment Registration
Vancouver, British Columbia--(Newsfile Corp. - May 5, 2025) - Optimi Health Corp. (CSE: OPTI) (OTCQX: OPTHF) (FSE: 8BN) ("Optimi" or the "Company"), a manufacturer of GMP-certified MDMA and psilocybin, has received its U.S. FDA Establishment Identifier (FEI) number—a key regulatory step for engaging in FDA filings and compliant supply into the United States.According to the U.S. Food and Drug Administration's Drug Establishments Current Registration Site (DECRS), "The publication is a list of currently registered establishments which manufacture, prepare, propagate, compound,...
2025-05-05 7:35 AM EDT
Optimi Health Provides Corporate Update
Vancouver, British Columbia--(Newsfile Corp. - March 12, 2025) - Optimi Health Corp. (CSE: OPTI) (OTCQX: OPTHF) (FSE: 8BN) ("Optimi" or the "Company"), a GMP-compliant, Health Canada-licensed manufacturer specializing in botanical psilocybin and MDMA, is pleased to provide the following corporate update, highlighting key regulatory milestones, clinical trial progress, and expanded market access.Expansion of MDMA Exports to the Australian MarketOptimi has received additional import permits for 1,000 doses of its GMP MDMA in 40mg and 60mg capsule formulations. This follows earlier...
2025-03-12 7:30 AM EDT
Optimi Health Completes Largest MDMA Capsule Batch to Date, Expands Stability Program
Vancouver, British Columbia--(Newsfile Corp. - January 29, 2025) - Optimi Health Corp. (CSE: OPTI) (OTCQX: OPTHF) (FSE: 8BN) ("Optimi" or the "Company"), a Canadian-based company licensed by Health Canada to produce and supply natural, GMP-grade psilocybin and MDMA, has completed its largest production batch of MDMA to date-over 4,000 GMP capsules, enough to treat more than 1,000 patients.As part of its commitment to ensuring long-term product stability and quality, Optimi has also completed one year of stability data on...
2025-01-29 7:30 AM EST
Optimi Health Announces Closing of Non-Brokered Private Placement and Debt Settlement
Vancouver, British Columbia--(Newsfile Corp. - January 28, 2025) - Optimi Health Corp. (CSE: OPTI) (OTCQX: OPTHF) (FSE: 8BN) ("Optimi" or the "Company"), a GMP-approved, Health Canada licensed psychedelics pharmaceutical manufacturer specializing in botanical psilocybin and MDMA, announces it has closed the second and final tranche (the "Second Tranche") of its non-brokered private placement (the "Offering") of units of the Company (each, a "Unit") at a price of $0.30 per Unit. Under the Second Tranche, the Company distributed 1,316,668 Units for...
2025-01-28 8:59 PM EST
Optimi Health Provides Corporate Update
Vancouver, British Columbia--(Newsfile Corp. - January 17, 2025) - Optimi Health Corp. (CSE: OPTI) (OTCQX: OPTHF) (FSE: 8BN) ("Optimi" or the "Company"), a GMP-approved, Health Canada licensed psychedelics pharmaceutical manufacturer specializing in botanical psilocybin and MDMA, announces it intends to close a second and final tranche of a non-brokered private placement by issuing 131,666 units (each a "Unit") at CAD$0.30 per Unit for gross proceeds of CAD$395,000 (the "Offering"), the first tranche of the Offering closed August 15, 2024. Each...
2025-01-17 5:00 PM EST
Optimi Health Reports First Patients Dosed in Landmark Natural Psilocybin Study in New Zealand
Vancouver, British Columbia--(Newsfile Corp. - January 13, 2025) - Optimi Health Corp. (CSE: OPTI) (OTCQX: OPTHF) (FSE: 8BN) ("Optimi" or the "Company"), a Health Canada-licensed manufacturer of psychedelic pharmaceuticals specializing in natural psilocybin and MDMA, is proud to announce that its natural psilocybin extract has been successfully exported to New Zealand. The shipment has enabled the dosing of the first participants using Optimi's natural psilocybin extract in a groundbreaking clinical trial supported by Tū Wairua, and the Mātai Medical Research...
2025-01-13 7:30 AM EST
Optimi Health Completes Second MDMA Shipment to Australia and Expands 2025 Production Forecast to Support Over 5,000 Patients Globally
Vancouver, British Columbia--(Newsfile Corp. - January 6, 2025) - Optimi Health Corp. (CSE: OPTI) (OTCQX: OPTHF) (FSE: 8BN) ("Optimi" or the "Company"), a Health Canada-licensed manufacturer of psychedelic pharmaceuticals specializing in natural psilocybin and MDMA, is pleased to announce the completion of its second shipment of GMP-certified MDMA capsules to Australia.Optimi has also increased its 2025 production forecast to supply enough MDMA capsules for over 5,000 patients globally. This expanded capacity highlights the Company's commitment to ensuring healthcare providers in...
2025-01-06 7:30 AM EST
Optimi Health to Supply GMP-Certified Psilocybin for Psyence Biomed's Phase IIb Palliative Care Trial
Agreement Supports Phase IIb and Future Phase III Trial Development,Addressing Critical Needs in Palliative Care Using Optimi's Natural Psilocybin ExtractVancouver, British Columbia--(Newsfile Corp. - December 17, 2024) - Optimi Health Corp. (CSE: OPTI) (OTCQX: OPTHF) (FSE: 8BN) ("Optimi" or the "Company"), a Canadian manufacturer of GMP-certified, naturally-derived psilocybin and MDMA, has entered into binding agreements with Psyence Biomedical Ltd. (Nasdaq: PBM) ("Psyence Biomed"). Under the terms of the agreement, Psyence Biomed will exclusively source GMP-certified psilocybin from Optimi for its...
2024-12-17 7:30 AM EST
Optimi Health Announces First PTSD Patients Treated with MDMA Capsules in Australia
Vancouver, British Columbia--(Newsfile Corp. - October 23, 2024) - Optimi Health Corp. (CSE: OPTI) (OTCQX: OPTHF) (FSE: 8BN) ("Optimi" or the "Company"), a Health Canada-licensed manufacturer of psychedelic pharmaceuticals specializing in botanical psilocybin and MDMA, is proud to announce that the first group of patients with post-traumatic stress disorder (PTSD) in Australia has successfully received treatment with its GMP-certified MDMA capsules under the Authorised Prescriber Scheme. In response to growing demand, the Company has received an additional order for 700...
2024-10-23 7:30 AM EDT
Optimi Health Announces Leadership Transition
Vancouver, British Columbia--(Newsfile Corp. - October 21, 2024) - Optimi Health Corp. (CSE: OPTI) (OTCQX: OPTHF) (FSE: 8BN) ("Optimi" or the "Company"), a GMP-compliant, Health Canada-licensed manufacturer of psychedelics specializing in botanical psilocybin and MDMA, today announced that Mr. William (Bill) Ciprick will be stepping down as Chief Executive Officer due to personal reasons."During his three years of leadership, Bill has played a key role in bringing Optimi's GMP psychedelics to market and to patients in Australia," said Optimi Co-Founder...
2024-10-21 7:30 AM EDT
Optimi Health & ATMA Receive No Objection Letter from Health Canada for Phase 2 Clinical Trial
Vancouver, British Columbia--(Newsfile Corp. - August 28, 2024) - Optimi Health Corp. (CSE: OPTI) (OTCQX: OPTHF) (FSE: 8BN) ("Optimi" or the "Company"), a GMP-compliant, Health Canada-licensed manufacturer of psychedelics pharmaceuticals specializing in botanical psilocybin and MDMA, is pleased to announce the receipt of a No Objection Letter (NOL) from Health Canada. This authorization permits the use of the Company's GMP natural psilocybin extract capsules in a Phase 2 clinical trial, conducted in collaboration with ATMA Journey Centers LTD. ("ATMA").Advancing Clinical...
2024-08-28 7:30 AM EDT
Optimi Health Completes Inaugural Export of MDMA Capsules to Australia for PTSD Treatment
Vancouver, British Columbia--(Newsfile Corp. - August 16, 2024) - Optimi Health Corp. (CSE: OPTI) (OTCQX: OPTHF) (FSE: 8BN) ("Optimi" or the "Company"), a GMP-approved, Health Canada-licensed psychedelics pharmaceutical manufacturer specializing in botanical psilocybin and MDMA, is pleased to announce it has completed the inaugural export of it's GMP-validated MDMA capsules to Australia for the treatment of PTSD, along with a series of notable corporate developments.MDMA Capsule Export to AustraliaThe Company is pleased to announce the successful export of its GMP-validated...
2024-08-16 7:30 AM EDT
Optimi Health and Psyence Biomedical Sign Non-Binding Letter of Intent to Advance Global Psilocybin Drug Development
Vancouver, British Columbia and New York, New York--(Newsfile Corp. - August 13, 2024) - Optimi Health Corp. (CSE: OPTI) (OTCQX: OPTHF) (FSE: 8BN) ("Optimi"), a GMP-approved, Health Canada licensed psychedelics pharmaceutical manufacturer specializing in botanical psilocybin and MDMA, and Psyence Biomedical Ltd. (NASDAQ: PBM) ("Psyence"), a developer of nature-derived psilocybin-based therapeutics, are pleased to announce that the companies have entered into a non-binding Letter of Intent ("LOI"). This arrangement would position Optimi as the exclusive supplier of GMP nature-derived (non-synthetic)...
2024-08-13 7:30 AM EDT
Optimi Health Announces Non-Brokered Private Placement
Vancouver, British Columbia--(Newsfile Corp. - August 7, 2024) - Optimi Health Corp. (CSE: OPTI) (OTCQX: OPTHF) (FSE: 8BN) ("Optimi" or the "Company"), a GMP-approved, Health Canada licensed psychedelics pharmaceutical manufacturer specializing in botanical psilocybin and MDMA, announces it intends to complete a non-brokered private placement of up to 16,666,666 units (each a "Unit") at CAD$0.30 per Unit for gross proceeds of up to CAD$5,000,000 (the "Offering").Each Unit comprised of one (1) common share in the capital of the Company (each...
2024-08-07 8:30 AM EDT
Optimi Health to Enter Asian Market with PsiloThai Collaboration on Psilocybin Research
Vancouver, British Columbia--(Newsfile Corp. - July 23, 2024) - Optimi Health Corp. (CSE: OPTI) (OTCQX: OPTHF) (FSE: 8BN) ("Optimi" or the "Company"), a GMP-approved, Health Canada licensed psychedelics pharmaceutical manufacturer specializing in botanical psilocybin and MDMA, is pleased to announce a strategic supply partnership and Letter of Intent with PsiloThai, a leading patient advocacy group registered in Thailand. This agreement marks a significant milestone as Optimi becomes the first psychedelics manufacturer to seek approval for its products to enter the...
2024-07-23 8:30 AM EDT
Optimi Health and Mind Medicine Australia Launch OptiMed Prescriber Portal for Australian Psychiatrists
Vancouver, British Columbia--(Newsfile Corp. - June 27, 2024) - Optimi Health Corp. (CSE: OPTI) (OTCQX: OPTHF) (FSE: 8BN) ("Optimi" or the "Company"), a Health Canada-approved, GMP-compliant pharmaceutical drug manufacturer specializing in the controlled substances MDMA and botanical psilocybin, is pleased to announce the launch of OptiMed, an online prescriber portal designed to provide Australian psychiatrists with comprehensive resources and support for prescribing psychedelic medicines safely and effectively through the Authorised Prescriber Scheme. This secure platform, a unique collaboration between Optimi...
2024-06-27 8:30 AM EDT
Health Canada Issues Three Export Permits to Optimi to Supply Patients Under Australia's Authorised Prescriber Scheme
Vancouver, British Columbia--(Newsfile Corp. - June 25, 2024) - Optimi Health Corp. (CSE: OPTI) (OTCQX: OPTHF) (FSE: 8BN) ("Optimi" or the "Company"), a Health Canada-approved, GMP-compliant pharmaceutical drug manufacturer specializing in the controlled substances MDMA and botanical psilocybin, is pleased to announce that it has received the three necessary export permits from Health Canada to supply GMP MDMA and psilocybin capsules for use in patients participating in Australia's Authorised Prescriber Scheme.Beginning with 160 doses, this milestone marks Optimi's commercial entry...
2024-06-25 8:30 AM EDT
Optimi Health Completes First International Shipment of MDMA to Israel and Secures CBSA Exporters Authorization ID
Vancouver, British Columbia--(Newsfile Corp. - June 11, 2024) - Optimi Health Corp. (CSE: OPTI) (OTCQX: OPTHF) (FSE: 8BN) ("Optimi" or the "Company"), a leading Health Canada licensed GMP psychedelics pharmaceutical manufacturer, specializing in controlled substances such as botanical psilocybin and MDMA, is pleased to announce a series of milestones in its international psychedelic supply operations and corporate marketing strategy.Optimi has completed its first international shipment to Israel of its in-house manufactured MDMA active pharmaceutical ingredient (API) to the Institute for...
2024-06-11 8:30 AM EDT